Based on the preclinical results of DNMT inhibitors or HDAC inhibitors, epigenetic drugs are undergoing clinical trial investigations for the treatment of recurrent resistant ovarian cancer [136]. This evidence concerns the gene DNMT1 and ovarian carcinoma.